ON DEMAND WEBINAR: The Ultimate Guide to Mouse Clinical Trials

Presented by Dr. John MacDougall this webinar presents Mouse Clinical Trials (MCT) using PDX models, and will help to guide you through the process of determining which MCT best suits the specific needs of any given drug development program.

NEW WHITE PAPER: A Guide to Selecting Your Next Immuno-Oncology Model

Improve your model selection decision for any immuno-oncology study by exploring the immunocompetent model types within this white paper. Learn more about the features, limitations and major uses of each type and how to apply them to your next study.

High Fidelity CRISPR Cell Line Engineering Services

Make better go/no-go decisions with CRISPR Engineered Cell Line Services.

CrownBio provides efficient, cost-effective gene editing services using licensed CRISPR/Cas9 technology. Our experts can generate knock in and knockout cell lines with vector controls that are tailored to meet your specific needs and help you advance your preclinical drug development programs.

Missed the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference?

Poster: Humanized CD137 Models for Preclinical Drug Development

Preclinical Efficacy Evaluation of Agonistic CD137 Therapeutic Antibodies in Human CD137 Knock-In Mouse Models (HuGEMM™)

ON DEMAND WEBINAR: How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Presented by Dr. Keefe Chng and Dr Judith Gorski this webinar will help guide you through a study design process that will enable the greatest opportunity to generate robust, high-quality data, that gives maximum confidence to select new drug candidates and regulatory submissions.

Didn't Make it to Tumor Models Boston 2017?

Poster: Evaluate Human Specific CD137 Antibodies

Preclinical Efficacy Evaluation of Agonistic CD137 Therapeutic Antibodies in Human CD137 Knock-In Mouse Models (HuGEMM™)

ON DEMAND WEBINAR: Vascular and Neural Complications in Rodent Models of Obesity and Type 2 Diabetes

Watch this scientific webinar presented by Dr. Mark Yorek, Professor of Medicine at University of Iowa and Associate Chief of Staff for Research at Iowa City VA. He will discuss the challenges in modeling diabetic neuropathy and how the use of improved translational rodent models can impact Diabetes and Obesity pre-clinical studies.

Didn't Make it to ADA 2017?

Watch our poster presentations and download our posters now!

1820-P: The Depletion of Peripheral NK Cells and NK T Lymphocytes in a Spontaneously Diabetic Non-Human Primate Model

1881-P: Rhythmic Differences of Blood Glucose Circadian between Normoglycemic and Diabetic Non-Human Primates

ON-DEMAND WEBINAR: Are You Choosing the Right Model?

A Guide to Selecting Your Next Immuno-Oncology Model

Join our webinar to discover the wide range of in vivo immuno-oncology preclinical models available, and what to consider when choosing the correct model for your studies. Learn how current models are being used to progress combination regimens, including dual immunotherapies, and I/O agents plus other treatment modalities.

NEW WHITE PAPER: Translational Platforms to Model Pre-Diabetes, Diabetes, and Diabetic Complications

This White Paper explores a unique platform of highly translational models recapitulating multiple aspects of disease progression as seen in humans, for preclinical efficacy studies.

ON-DEMAND WEBINAR: Translational Platforms to Model Pre-Diabetes, Diabetes, and Complications

Join our webinar to discover the development and utility of CrownBio's unique continuum of translational platforms modeling diabetes and metabolic syndrome pathophysiology, progression, and complications. Learn how these platforms are predicting the efficacy and safety of anti-diabetic therapies in humans.

Didn't Make it to AACR 2017?

Read and download all of our 14 posters now!

Clarity with
Crown

Recognize your next clinical candidate when you see it.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Magnify your
insights

Understand the mechanisms of disease.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

Begin with the
end insight

Connecting science to patients.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

September 21, 2017

Blood Cancer PDX Models: Focus on Acute Myeloid Leukemia‎

A number of our previous posts have covered the benefits of patient-derived xenografts (PDX), usually focusing on models derived from solid tumors. But these highly predictive preclinical models can also be developed from blood cancer.

Read More

September 21, 2017

Blood Cancer PDX Models: Focus on Acute Myeloid Leukemia‎

A number of our previous posts have covered the benefits of patient-derived xenografts (PDX),...

Read More

September 19, 2017

Beginners Guide: Humanized Drug Target Immuno-Oncology Models

Our recent post compared stable vs transiently humanized models, which are needed when...

Read More

September 12, 2017

CD137: An Important Target in T Cell Co-Stimulation

Following on from OX40, our TNF superfamily posts continue with CD137, another important target...

Read More

September 7, 2017

When to Use Stable vs Transiently Humanized I/O Models

As immunotherapeutics continue to dominate oncology headlines and research, more preclinical...

Read More

Upcoming Events


September 26 - 28, 2017

The 3rd DIA China Drug Discovery Innovation Conference

Jiangsu, China

www.eventbank.cn/event/9977/


September 29 - 30, 2017

25th Annual SAPA Conference

New Jersey

www.sapaweb.org


October 1 - 4, 2017

Tumor Immunology and Immunotherapy

Boston, MA

www.aacr.org/Meetings/Pages/MeetingDetail
Review our Scientific Posters


October 20 - 24, 2017

American Association for the Study of Liver Disease: The Liver Meeting® 2017

Washington D.C.

www.aasld.org/events-professional-development/liver-meeting


October 26 - 30, 2017

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications

Booth #601, Philadelphia, PA

www.aacr.org
Review our Scientific Posters


November 6 - 9, 2017

4th AACR New Horizons in Cancer Research Conference: Research Propelling Cancer Prevention and Cures

Shanghai, China

www.nhicr.aacr.asia


November 9 - 11, 2017

First EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit:

Rome, Italy

Target-Oriented approach to Diagnosis and Pharmacotherapy of Nonalcoholic Steatohepatitis (NASH), a dialogue between Academia and Industry

www.events.easl.eu